FDA Mandates Guillain-Barré Syndrome Warning for Two RSV Vaccines
The FDA has required Guillain-Barré syndrome warnings to be added to prescribing information for RSV vaccines Abrysvo and Arexvy.
Category: RSV
RSV
Latest
FDA Mandates Guillain-Barré Syndrome Warning for Two RSV Vaccines
The FDA has required Guillain-Barré syndrome warnings to be added to prescribing information for RSV vaccines Abrysvo and Arexvy.
Read More
RSV Vaccine Effectiveness Lower in Immunocompromised Older Adults
Johns Hopkins Medicine says further research is needed to better understand the problem and find ways to enhance immune response in this high-risk population.
Read More
Best Window for RSV Vaccination During Pregnancy Identified
Current guidelines recommend RSV vaccination between 32-36 weeks of pregnancy, but researchers have identified the optimal time within that window for maximum newborn protection.
Read More
Pfizer’s RSV Vaccine Approved for Adults Down to Age 18
The FDA has approved Pfizer’s RSV vaccine, Abrysvo, for adults aged 18 to 59 who are at increased risk of lower respiratory tract disease caused by RSV, expanding its previous indication for adults aged 60 and older.
Read More
RSV Is Linked to Asthma in Children – But We Can’t Say One Causes the Other Yet
While respiratory syncytial virus, or RSV, is strongly associated with asthma in children, the exact relationship remains unclear.
Read More
Pfizer’s RSV Vaccine Shows Promise in Immunocompromised Adults
Pfizer’s Abrysvo demonstrated a strong immune response and favorable safety profile in immunocompromised adults at high risk of severe RSV.
Read More
Under 75? CDC Revises RSV Vaccine Recommendations for High-Risk Only
The CDC’s updated guidance recommends vaccination only for high-risk adults aged 60-74, while strengthening its advice for adults 75 and older.
Read More
FDA Expands Approval of Arexvy for Adults Age 50-59
GlaxoSmithKline’s RSV vaccine Arexvy is now available for at-risk adults age 50-59 in addition to those age 60 and older.
Read More
FDA Approves Moderna RSV Vaccine
mRESVIA is the first mRNA vaccine approved for a disease other than COVID-19 and is the only RSV vaccine available in single-dose pre-filled syringes.
Read More
Tool Identifies Newborns at Highest Risk for Severe RSV
Researchers have created a new tool to identify newborns at the highest risk for severe RSV, enhancing the prioritization of immunoprophylaxis during shortages.
Read More
PAHO Report on Respiratory Virus Circulation
News Brief: Pan American Health Organization The Pan American Health Organization (PAHO) this week...
Read More
The Overlooked Phenomenon of ‘Long Colds’
Scientists suggest that extended ailments, termed “long colds,” can also arise from non-COVID respiratory infections.
Read More
Decongestant in Popular OTC Cold and Allergy Meds Doesn’t Work, FDA Panel Says
An FDA advisory committee determined that phenylephrine, common in brands like Benadryl and Mucinex, is ineffective as a nasal decongestant.
Read More
Most Infants Receiving ICU-level Care for RSV Were Previously Healthy
A CDC-supported study found the majority of infants admitted to the intensive care or high acuity unit for RSV during fall 2022 were previously healthy and born at term.
Read More
Pediatric Asthma Diagnoses Declined 52% During Pandemic
Half as many children in the United States were diagnosed with asthma in the first year of the COVID-19 pandemic compared to previous years, perhaps due to a fewer number of common colds, according to Rutgers University researchers.
Read More
Sulforaphane in Broccoli Slowed COVID, Common Cold
Sulforaphane, a plant-derived chemical found in broccoli and other leafy vegetables, can inhibit the replication of COVID and another human coronaviruses in cells and mice.
Read More
Rhinovirus, Enterovirus Continued to Circulate During Pandemic
While flu, RSV, and other respiratory virus infections declined sharply, rhinovirus/enterovirus persisted and continued to circulate among children.
Read More
Rhinovirus an Ally Against Influenza
New data published in The Lancet Microbe reveals that rhinovirus can jumpstart the immune system and prevent influenza infections.
Read More
Can You Die from a Common Cold?
Rhinovirus causes about half of all colds, but other viruses can cause one or more of the symptoms of a cold, including adenovirus, influenza virus, respiratory syncytial virus and parainfluenza virus.
Read More
Bump It: Fist Bumps Transfer Less Germs than Handshakes
Study results found nearly twice as many bacteria were transferred during a handshake compared to the high‐five, and significantly fewer bacteria were transferred during a fist bump than a high‐five.
Read More
FDA Launches Cure ID App for Infectious Disease Reporting
The US FDA has launched Cure ID, which will allow clinicians to report infectious disease treatments via a smartphone app.
Read More
Fewer Neonatal Respiratory Infections When Babies Have Well-connected Microbiota
Researchers have shown how microbial communities are linked to each other across the body and how these networks are associated with susceptibility to respiratory infections in babies.
Read MoreScientists Honing in on Cure to the Common Cold
Researchers have discovered a protein in human cells that, when deleted, prevented the spread of rhinovirus and could be a cure to the common cold, according to research in Nature Microbiology.
Read More
FDA Urges Vaccinations for Back-to-School Season
“We cannot state strongly enough that overwhelming scientific evidence shows that vaccines are among the most effective and safest interventions, to both prevent individual illness and protect public health,” the FDA said.
Read More